MLAB लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

बेचें 107317 min ago

@ $92.30

जारी किया गया: 14 Feb 2024 @ 20:10

वापसी: 11.80%

पिछला सिग्नल: Feb 13 - 20:00

पिछला सिग्नल: खरीदें

वापसी: 0.53 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 01:30):

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally...

Stats
आज की मात्रा	18 627.00
औसत मात्रा	43 153.00
बाजार मूल्य	556.61M
EPS	$0 ( 2024-02-05 )
अगली कमाई की तारीख	( $2.33 ) 2024-05-24
Last Dividend	$0.160 ( 2023-11-29 )
Next Dividend	$0 ( N/A )
P/E	607.00
ATR14	$0.497 (0.48%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Sullivan John James	Sell	450	Non Qualified Stock Option
2024-04-02	Sakys John	Sell	2 500	Non Qualified Stock Option
2024-04-02	Owens Gary M	Sell	5 000	Non Qualified Stock Options
2024-04-02	Archbold Brian David	Sell	420	Non Qualified Stock Option
2024-01-08	Archbold Brian David	Sell	290	Non Qualified Stock Option

INSIDER POWER
12.65
Last 100 transactions
Buy: 73 301 \| Sell: 52 584

मात्रा सहसंबंध

लंबा: 0.28 (neutral)

छोटा: 0.08 (neutral)

Signal:(52.194) Neutral

Mesa Laboratories Inc सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Mesa Laboratories Inc सहसंबंध - मुद्रा/वस्त्र

0.66
( moderate )

0.59
( weak )

0.30
( neutral )

0.53
( weak )

-0.60
( weak negative )

0.15
( neutral )

Mesa Laboratories Inc वित्तीय

Annual	2023
राजस्व:	$219.08M
सकल लाभ:	$133.69M (61.02 %)
EPS:	$0.170

FY	2023
राजस्व:	$219.08M
सकल लाभ:	$133.69M (61.02 %)
EPS:	$0.170

FY	2022
राजस्व:	$184.34M
सकल लाभ:	$109.09M (59.18 %)
EPS:	$0.360

FY	2021
राजस्व:	$133.94M
सकल लाभ:	$87.01M (64.97 %)
EPS:	$0.660

Financial Reports:

No articles found.

Mesa Laboratories Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.160 (N/A)	$0.160 (N/A)	$0.160 (N/A)	$0.160 (N/A)	$0.160 (N/A)	$0.160 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Mesa Laboratories Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 7.61 - good (76.09%) | Divividend Growth Potential Score: 5.87 - Stable (17.38%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.200	2003-11-26
Last Dividend	$0.160	2023-11-29
Next Dividend	$0	N/A
Payout Date	2023-12-15
Next Payout Date	N/A
# dividends	81	--
Total Paid Out	$11.06	--
Avg. Dividend % Per Year	0.19%	--
Score	4.41	--
Div. Sustainability Score	7.61
Div.Growth Potential Score	5.87
Div. Directional Score	6.74	--

Next Divdend (Est)
(2024-07-01)

$0.164 Estimate 39.63 %

Dividend Stability

0.79 Good

Dividend Score

4.41

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2003	$0.200	3.07%
2004	$0.410	4.07%
2005	$0.500	3.85%
2006	$0.390	2.60%
2007	$0.340	1.80%
2008	$0.400	1.54%
2009	$0.410	2.27%
2010	$0.450	1.70%
2011	$0.490	1.63%
2012	$0.530	1.29%
2013	$0.570	1.08%
2014	$0.610	0.79%
2015	$0.640	0.80%
2016	$0.640	0.64%
2017	$0.640	0.52%
2018	$0.640	0.51%
2019	$0.640	0.31%
2020	$0.640	0.26%
2021	$0.640	0.23%
2022	$0.640	0.20%
2023	$0.640	0.37%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.00445	1.500	9.91	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00128	1.200	9.96	10.00	[0 - 0.3]
returnOnEquityTTM	0.00241	1.500	-1.084	-1.626	[0.1 - 1]
payoutRatioTTM	3.63	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	2.68	0.800	1.606	1.285	[1 - 3]
quickRatioTTM	1.503	0.800	5.87	4.69	[0.8 - 2.5]
cashRatioTTM	0.639	1.500	7.56	10.00	[0.2 - 2]
debtRatioTTM	0.318	-1.500	4.70	-7.04	[0 - 0.6]
interestCoverageTTM	-2.03	1.000	-1.862	-1.862	[3 - 30]
operatingCashFlowPerShareTTM	8.12	2.00	7.29	10.00	[0 - 30]
freeCashFlowPerShareTTM	7.55	2.00	6.23	10.00	[0 - 20]
debtEquityRatioTTM	0.586	-1.500	7.66	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.610	1.000	3.16	3.16	[0.2 - 0.8]
operatingProfitMarginTTM	-0.0438	1.000	-2.88	-2.88	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.185	1.000	-0.0812	-0.0812	[0.2 - 2]
assetTurnoverTTM	0.287	0.800	-1.420	-1.136	[0.5 - 2]
Total Score				7.61

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	587.03	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.00241	2.50	-0.697	-1.626	[0.1 - 1.5]
freeCashFlowPerShareTTM	7.55	2.00	7.48	10.00	[0 - 30]
dividendYielPercentageTTM	0.620	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	8.12	2.00	7.29	10.00	[0 - 30]
payoutRatioTTM	3.63	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	1.693	1.500	2.05	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.206	1.000	7.36	0	[0.1 - 0.5]
Total Score				5.87

Mesa Laboratories Inc

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.